SLN · Annual Report (Form 10-K) · Filed March 5, 2026

Silence Therapeutics PLC — 10-K exhibit

sln-ex10_15.htm

Silence Therapeutics PLC on Boardroom Alpha

EX-10.15

Exhibit 10.15

14 December 2025

Via email: ***

Addendum to your 19 July 2025 Letter of Appointment as Chairman

Dear Iain:

Effective 14 December 2025, Silence Therapeutics Plc will increase your remuneration to £25,000 per month for a period of six months, during which you will serve as Chair of the Company with executive responsibilities. Following this initial term, the arrangement may continue on a monthly basis by mutual agreement.

Also, an award of 300,000 ADSs will be granted as of 14 December 2025. Any monetary bonus will be determined after further discussion by the Remuneration Committee.

All other terms and conditions of your engagement are unchanged.

Yours Sincerely,

/s/Tim McInerney

Tim McInerney

Chair, Remuneration Committee

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer